Search

Your search keyword '"Hernández‐Rivas, J.‐Á."' showing total 12 results
Start Over Author "Hernández‐Rivas, J.‐Á."
12 results on '"Hernández‐Rivas, J.‐Á."'

2. S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA

Author

Wang, M. L., primary, Jurczak, W., additional, Jerkeman, M., additional, Trotman, J., additional, Zinani, P. L., additional, Belada, D., additional, Boccomini, C., additional, Flinn, I. W., additional, Giri, P., additional, Goy, A., additional, Hamlin, P. A., additional, Hermine, O., additional, Hernández-Rivas, J.-Á., additional, Hong, X., additional, Kim, S. J., additional, Lewis, D., additional, Mishima, Y., additional, Özcan, M., additional, Perini, G. F., additional, Pocock, C., additional, Song, Y., additional, Spurgeon, S. E., additional, Storring, J. M., additional, Walewski, J., additional, Zhu, J., additional, Qin, R., additional, Henninger, T., additional, Deshpande, S., additional, Howes, A., additional, Le Gouill, S., additional, and Dreyling, M., additional

Published
2022
Full Text
View/download PDF

3. P622: DOUBLE-HIT TRAF3 DELETION AND MUTATION IDENTIFIED BY HIGH-THROUGHPUT SEQUENCING DEFINE A NEW INDEPENDENT PROGNOSTIC FACTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA

Author

Perez-Carretero, C., primary, Hernández-Sánchez, M., additional, Quijada-Álamo, M., additional, González, T., additional, Rodríguez-Sánchez, A., additional, Martín-Izquierdo, M., additional, Matías-Martín, J., additional, Rubio, A., additional, Dávila, J., additional, García de Coca, A., additional, Galende, J., additional, Jimenez-Montero, P., additional, Queizán, J.-A., additional, González-Gascón y Marín, I., additional, Hernández-Rivas, J.-Á., additional, Benito, R., additional, Hernández-Rivas, J.-M., additional, and Rodríguez-Vicente, A.-E., additional

Published
2022
Full Text
View/download PDF

4. P1136: INTERIM IMAGING DOES NOT PREDICT CLINICAL EVOLUTION IN FOLLICULAR LYMPHOMA IN A REAL-LIFE CLINICAL SETTING

Author

Ramos De Ascanio, V., primary, Sánchez Paz, L., additional, Infante, M. S., additional, Churruca Sarasqueta, J., additional, Foncillas García, M. Á., additional, Landete Hernández, E., additional, Marín Mori, K. D. C., additional, Muñoz Novas, C., additional, Hernández Rivas, J. Á., additional, and González Gascón y Marín, I., additional

Published
2022
Full Text
View/download PDF

5. P1608: EXPERIENCE AND COMPLICATIONS WITH THE USE OF PICCS IN HEMATOLOGIC PATIENTS

Author

Sanchez-Paz, L., primary, Solaeta Gómez, M. J., additional, Varona Torralvo, N., additional, Molina Mejías, P., additional, Valencia Ospina, E., additional, Rodriguez Calderita, M. A., additional, Díez Viñas, V., additional, Ramos de Ascanio, V., additional, Muñoz Novas, C., additional, Churruca, J., additional, Infante, M. S., additional, Landete, E., additional, Marín, K., additional, Foncillas, M. Á., additional, Hernández-Rivas, J.-Á., additional, and González-Gascón-y-Marín, I., additional

Published
2022
Full Text
View/download PDF

6. P1128: CLINICAL FEATURES AND OUTCOME OF PATIENTS WITH CASTLEMAN DISEASE: A SPANISH MULTICENTRIC STUDY OF 134 PATIENTS FROM GELTAMO

Author

Navarro, J. T., primary, Celades, C., additional, García, O., additional, González-Barca, E., additional, Climent, F., additional, Feu, A., additional, Jiménez, A., additional, Gutiérrez de la Peña, A., additional, Bastos-Oreiro, M., additional, Aldamiz-Echevarria, T., additional, Gutiérrez, A., additional, Bento, L., additional, Abrisqueta, P., additional, Alonso, C. M., additional, Tejada Chavez, C., additional, Ocio, E. M., additional, Fernández Escalada, N., additional, Navarro Matilla, M. B., additional, Mateos Pérez, J. M., additional, López-García, A., additional, Castillo-Girón, C., additional, Pinzón, S. F., additional, Pérez Ceballos, E., additional, Hernández Rivas, J. Á., additional, del Campo García, R., additional, Pardal de la Mano, E., additional, García-Sanz, R., additional, Rovira, J., additional, Sancho, J. M., additional, and Tapia, G., additional

Published
2022
Full Text
View/download PDF

7. P1541: PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT.

Author

Serrano-Gonzalo, I., primary, López de Frutos, L., additional, Arévalo-Vargas, I., additional, Fernández-Galán, M. Á., additional, Morales-Conejo, M., additional, Calle-Gordo, M. V., additional, Vitoria-Miñana, I., additional, Correcher-Medina, P., additional, Madinaveitia-Ochoa, A., additional, Hernández-Rivas, J. Á., additional, García-Frade, J., additional, Ibarretxe-Gerediaga, D., additional, Delgado-Mateos, F., additional, Tormo-Díaz, M. D. M., additional, Ruíz-Guinaldo, M. Á., additional, Mora-Casterá, E., additional, Noya-Pereira, M. S., additional, Albarracín-Arraigosa, A., additional, López-Dupla, M., additional, Balanzat-Muñoz, J., additional, Lozano-Almela, M. L., additional, Labbadia, F., additional, Andrade-Campos, M., additional, and Giraldo, P., additional

Published
2022
Full Text
View/download PDF

8. Treatment of High-Risk Acute Lymphoblastic Leukemia. Preliminary Results of the Protocol PETHEMA ALL-93

Author

PETHEMA Cooperative Group. Spanish Society of Hematology, Ribera, J. M., Ortega, J. J., Oriol, A., Fontanillas, M., Maldonado, J., Parody, R., Rivas, C., Hernández-Rivas, J. M., Terol, M. J., Bastida, P., González-Valentín, M. E., Feliu, E., García-Conde, J., Díaz-Mediavilla, J., San Miguel, J. F., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

9. Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively

Author

Moreno, Carol, Muñoz, C., Terol, M. J., Hernández-Rivas, J. Á., Villanueva, Miguel, and Universitat Autònoma de Barcelona

Subjects
Cancer Research, Chronic lymphocytic leukemia, Tumor burden, Disease, Review, Immune function, Immune Dysfunction, chemistry.chemical_compound, Therapeutic approach, Immune system, Humans, Medicine, Chronic Lymphocytic Leukemia, PI3K/AKT/mTOR pathway, RC254-282, business.industry, Ibrutinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Oncology, chemistry, Cancer research, Immunotherapy, business, CLL
Abstract

Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by uncontrolled proliferation of B-cells and severe immune dysfunction. Chemo(immuno)therapies (CIT) have traditionally aimed to reduce tumor burden without fully understanding their effects on the immune system. As a consequence, CIT are usually associated with higher risk of infections, secondary neoplasms and autoimmune disorders. A better understanding of the biology of the disease has led to the development of therapeutic strategies which not only act against malignant B-cells but also reactivate and enhance the patient’s own anti-tumor immune response. Here, we review the current understanding of the underlying interplay between the malignant cells and non-malignant immune cells that may promote tumor survival and proliferation. In addition, we review the available evidence on how different treatment options for CLL including CIT regimens, small molecular inhibitors (i.e, BTK inhibitors, PI3K inhibitors, BCL-2 inhibitors) and T-cell therapies, affect the immune system and their clinical consequences. Finally, we propose that a dual therapeutic approach, acting directly against malignant B-cells and restoring the immune function is clinically relevant and should be considered when developing future strategies to treat patients with CLL.

Published
2021

10. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

Author

Martínez-López, Joaquín, Mateos, M. V., Encinas, C., Sureda, A., Hernández-Rivas, J. Á., Lopez de la Guía, A., Conde, D., Krsnik, I., Prieto, E., Riaza Grau, R., Gironella, Mercedes, Blanchard, M. J., Caminos, N., Fernández de Larrea, C., Senin, Alicia., Escalante, F., de la Puerta, J. E., Giménez, E., Martínez-Barranco, P., Mateos, J. J., Casado Montero, Luis Felipe, Bladé, J., Lahuerta, J. J., De la Cruz, Javier, San-Miguel, J., Universitat Autònoma de Barcelona, Martínez-López, Joaquín, Mateos, Maria Victoria, Lahuerta, Juan José, San-Miguel, Jesús, Martínez-López, Joaquín [0000-0001-7908-0063], Mateos, Maria Victoria [0000-0003-2390-1218], Lahuerta, Juan José [0000-0002-3393-9570], San-Miguel, Jesús [0000-0002-9183-4857], Institut Català de la Salut, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, Multivariate analysis, Epidemiology, Myeloma, Disease, Comorbidity, técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::mortalidad [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Kidney, COVID-19 (Malaltia), Severity of Illness Index, 0302 clinical medicine, Multiple myeloma, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Hospitalization, Oncology, 030220 oncology & carcinogenesis, Cohort, Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Infectious diseases, Female, Drug therapy, Coronavirus Infections, Multiple Myeloma, medicine.medical_specialty, Pronòstic mèdic, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, lcsh:RC254-282, Article, 03 medical and health sciences, Betacoronavirus, Pharmacotherapy, Internal medicine, Severity of illness, Mortalitat, medicine, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Humans, Pandemics, Aged, Inpatients, Inpatient mortality, business.industry, SARS-CoV-2, Mieloma múltiple, COVID-19, medicine.disease, Pneumonia, Increased risk, business, 030215 immunology
Abstract

There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.

Published
2020

11. CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial

Author

Kim, W.S., primary, Coiffier, B., additional, Buske, C., additional, Ogura, M., additional, Kwak, L., additional, Jurczak, W., additional, Sancho, J.M., additional, Zhavrid, E., additional, Kim, J.S., additional, Hernández-Rivas, J-Á, additional, Prokharau, A., additional, Vasilica, M., additional, Nagarkar, R., additional, Lee, S.J., additional, Lee, S.Y., additional, and Bae, Y.J., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results